



Pathogenesis and Natural History of Myeloproliferative Neoplasms

Guest Editor:

Dr. Marco Pizzi

Pathology Unit, Department of
Medicine—DIMED, University of
Padova School of Medicine,
35128 Padova, Italy

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Myeloproliferative Neoplasms (MPNs) are a heterogeneous group of clonal hemopoietic stem cell disorders with unique clinical-pathological and molecular features.

Over the last decades, the field of MPNs has undergone dramatic changes, as a consequence of a better understanding of their biology and natural history. Driver genetic events (e.g. BCR-ABL1 fusion gene; JAK2, CALR and/or MPL mutations) and MPN-related molecular derangements have been widely characterized and have fostered the development of new target therapies. MPNs are thus a paradigmatic example of how the integration of basic sciences and applied research expands our knowledge of human diseases and improves their clinical management.

Within this framework, this Special Issue will address the pathogenesis, molecular biology and natural history of Chronic Myeloid Leukemia, Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis and cutaneous/systemic Mastocytosis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)